My new Clinical Pipeline column is out in Nature Medicine.
It's on JAK inhibitors for alopecia - and at the black box safety warning the FDA attached to this entire class of drugs.
#Immunology #drugdiscovery #drugdevelopment #alopecia
@gpollara I don't think we have enough data on that - the group that generated the warning (in another trial set) was oder and had a range of pre-existing conditions.
@gpollara and thanks!
@cyrilpedia interesting. You can see how a signal came out in that population. My hunch is that it's time & dose dependent, but that doesn't massively help in autoimmune conditions in which treatment is long, spanning into years potentially.
Thank you.
@gpollara I agree completely - this is a lifelong treatment. I'm in NY right now and the advertisements for ruxolitinib are everywhere.
@cyrilpedia honestly, speaking from a UK perspective, the idea that (obviously non-generic) drugs are marketed straight to patients utterly bemusing!
Is the idea genuinely that the half-informed patient sees it and then goes to their doctor asking about/for it?!
@gpollara I couldn't agree with you more.
@cyrilpedia nice piece, and also informative. Had missed the black box warning on the whole JAK Stat family! Is the increased cardiovascular risk dose / time dependent, or is it idiosyncratic?